Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OCT- clear · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational Product #1 (IP1) | EXPERIMENTAL | octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear |
| Investigational Product #2 (IP2) | EXPERIMENTAL | octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted |
| Active Control | ACTIVE_COMPARATOR | ChloraPrep® - Hi-Lite Orange® applicator |
| Negative Control | PLACEBO_COMPARATOR | sterile 0.9% saline applied with single use applicator |
| Name | Type | Description |
|---|---|---|
| OCT - clear | DRUG | Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear |
| OCT- tinted | DRUG | Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted |
| ChloraPrep | OTHER | Active Control: ChloraPrep® - Hi-Lite Orange® applicator |
| Saline | OTHER | Negative Control: sterile 0.9% saline applied with single use applicator |
Inclusion Criteria: * Subjects may be of either sex, at least 18 years of age and of any race. * Subjects must be in good general health. * Subjects must read and sign an Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and the List of Restricted Products ...
OCT-clear is an investigational small molecule developed by Becton, Dickinson and Company for preoperative skin preparation. It is designed as an antimicrobial agent applied to the skin before surgery. It has completed a Phase 2 clinical trial and is not yet approved for commercial use.
OCT-clear is being studied for preoperative skin preparation, meaning it is intended to reduce microorganisms on the skin before a surgical procedure. Its only recorded clinical trial enrolled healthy adult volunteers aged 18 and older in the United States, evaluating its effectiveness as an antimicrobial skin preparation agent.
OCT-clear is developed by Becton, Dickinson and Company, which trades under the ticker BDX. The company sponsored the Phase 2 study of the agent for preoperative skin preparation. No partnership or licensing arrangement for OCT-clear is disclosed.
OCT-clear has completed a Phase 2 clinical trial and remains investigational. It is not approved by the FDA for preoperative skin preparation. The Phase 2 study has been completed, and no active trials are currently listed for this asset.
OCT-clear has been evaluated in one completed Phase 2 trial, NCT03224299, titled Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation. The study enrolled 131 healthy adult volunteers in the United States, was randomized, double-blind, and placebo-controlled, and has finished.
Yes, OCT-clear and OCT - clear refer to the same investigational product from Becton, Dickinson and Company. The spacing and hyphenation vary between sources, but both names describe the same antimicrobial agent studied for preoperative skin preparation in the completed Phase 2 trial NCT03224299.